One of the key focus area of Rus BioPharm is development of Biological and Biosimilar Drug Products for severe Rheumatology, Onco-Hematology, Gastroenterology and Reproductive disorders.
INN;Drug Form;Stage of Development
Adalimumab;solution for subcutaneous injection;MA received
Etanercept;solution for subcutaneous injection;MA received
Pegfilgrastim;solution for subcutaneous injection;MA received
Darbepoetin alpha;solution for subcutaneous injection;Clinical trial phase III on-going
Eptacog alpha;lyophilizate for solution for intravenous injection;MA received
Nadroparin calcium;solution for subcutaneous injection;MA received
Tenecteplase;lyophilizate for solution for intravenous injection;Clinical studies on-going
Ranibizumab;solution for intravitreal injection;Clinical studies on-going
7 additional Biosimilars in different stages of development
Inhalation Drugs
Pulmonology is one of the key focus areas for Rus BioPharm and Rus BioPharm is developing a wide range of Inhalation Drugs Products for Asthma and Chronic Obstructive Pulmonary Disease, in all possible Drug Forms: Aerosols, Powders, Solutions and Suspensions for inhalation
Metered Dose Inhalers
INN;Drug Form;Stage of Development
Salmeterol + Fluticasone;Metered Dose Inhaler;MAs for Russia and Uzbekistan received
Ipratropium + Fenoterol;Metered Dose Inhaler;MA received
Formoterol + Budesonide;Metered Dose Inhaler;In the process of MA approval
Formoterol;Metered Dose Inhaler;MA received
Ipratropium bromide;Metered Dose Inhaler;MA received
Fluticasone;Metered Dose Inhaler;MA received
Beclometasone;Metered Dose Inhaler;MA received
Beclomethasone+ Formoterol;Metered Dose Inhaler;MA received
Salbutamol;Metered Dose Inhaler;MA received
Ciclesonide;Metered Dose Inhaler;MA received
LABA+LAMA;Metered Dose Inhaler;Pharmaceutical development
LABA+LAMA+ICS;Metered Dose Inhaler;Pharmaceutical development
And more than 4 innovative products at the development stage
Dry Powder Inhalers
INN;Drug Form;Stage of Development
Salmeterol + Fluticasone;Dry Powder Inhaler;MAs for Russia and Uzbekistan received
Formoterol + Budesonide;Dry Powder Inhaler;MAs for Russia and Uzbekistan received
Formoterol + Budesonide (set);Dry powder inhaler;MA received
Formoterol;Dry Powder Inhaler;MA received
Budesonide;Dry Powder Inhaler;MA received
Tiotropium;Dry Powder Inhaler;MA received
Glycopyrronium bromide;Dry Powder Inhaler;MA received
Indacaterol;Dry Powder Inhaler;In the process of MA approval
Glycopyrronium bromide + Indacaterol;Dry Powder Inhaler;MA received
And more than 5 innovative products at the development stage (R&D)
Solutions and Suspensions for Inhalation
INN;Drug Form;Stage of Development
Ipratropium bromide;SFI;MA received
Ipratropium bromide+ Fenoterole;SFI;MA received
Tobramycin;SFI;MA received
Colistimethate sodium;lyophilizate for solution for inhalation;MA received
Budesonide;SFI;MA received
Budesonide;Suspension for inhalation;Clinical trials
Fenoterol;SFI;MA received
More than 7 products are under development
Sterile Injectables
Rus BioPharm is developing a wide range of Drugs Products for Hospital segment, such as new generation Antibiotics, Antimycotics, Proton pump inhibitors and a number of other Drugs from the Essential Drugs List, in 3 Drug forms: lyophilizates, Solutions and Concentrates.
INN;Drug Form;Stage of Development
Icatibant;solution for subcutaneous injection;MA received
Tigecycline;lyophilizate for solution for infusion;MAs for Russia and Belarus received
Daptomycin;lyophilizate for solution for infusion;MA received
Dexmedetomidine;concentrate for solution for infusion;MA received
Azithromycin;concentrate for solution for infusion;MA received
Famotidine;lyophilizate;MA received
Micafungin;lyophilizate;MAs for Russia and Belarus received
Omeprazole;lyophilizate;MA received
Esomeprazole;lyophilizate;MAs for Russia and Uzbekistan received
Levosimendan;concentrate;MA received
Fosaprepitant;lyophilizate;MA received
Rabeprazole;lyophilizate;MA received
Fondaparinux sodium;Solution for intravenous and subcutaneous injection;MA received
Caspofungin;lyophilizate;Pharmaceutical development
Anidulafungin;lyophilizate;MA received
Voriconazole;lyophilizate;MA received
Aflibercept;Solution for injection; Clinical trial phase III
More than 13 products are under development
Solid Dosage Forms
Rus BioPharm's OSD Drug Product range covers diseases such as HIV, Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, etc.
INN;Drug Form;Stage of Development
Valganciclovir;Tablets;MA received
Fosamprenavir*;Tablets;MA received
Tofacitinib*;Tablets;MA received
Dimethylfumarate;Capsules;MA received
Cinacalcet;Tablets;MA received
Aprepitant;Capsules;MA received
Sevelamer;Tablets;MA received
Rivaroxaban;Tablets;BE study
Deferasirox;Dispersible tablets;MA received
Deferasirox;Film-coated tablets;MA received
Raltegravir;Film-coated tablets;MA received
Teriflunomide;Film-coated tablets;MA received
PASK;Film-coated tablets;MA received
Ticagrelor;Film-coated tablets;Pharmaceutical development
Etravirine;Tablets;MA received
Dabigatran;Capsules;BE study
Macitentan;Film-coated tablets;MA received
Lopinavir + Ritonavir;Film-coated tablets;MA received
Ritonavir;Film-coated tablets;MA received
Lacosamide;Tablets;MA received
Nirmatrelvir;Tablets;MA received
More than 15 products are under development
Pharmaceutical Capabilities
Metered Dose Inhalers
Dry Powder Inhalers
Metered Dose Solutions for Inhalation
Lyophilizates
Solutions and Concentrates for Injections
Solid Dosage Forms
Biological Drugs and Biosimilars – Injectable Solutions
Kilo Lab for API synthesis
Bioprocessing unit with USP and DSP
Contacts
Headquarters
15, 1st Krasnogvardeysky lane, 39th floor, Mercury Tower, Moscow International Business Center, 123112, Russian Federation, Phone: +7 499 400 16 99 E-mail: office@rusbiopharm.ru
Manufacturing Facility
4, Programmistov Street, bld.2, off.215, Special Economic Zone "Dubna" Dubna, Moscow Region Russian Federation, 141983 Phone: +7 496 218 19 19 E-mail: office1@rusbiopharm.ru
Website content is intended for medical professionals only. Please confirm whether you are a medical professional. If you are not a medical professional, please leave this website section.